LLY · News · 20261102N
Guidance and Outlook
ELI LILLY & Co · 2026-11-02 · Importance 60 · Surprise 24 · In source text
The article reports that Lilly’s full-year 2026 revenue guidance is $91 billion to $92 billion. It says the outlook follows strong demand for Mounjaro and Zepbound, alongside a tradeoff between rising volume and lower realized prices. The report provides no additional timeframe or quantified margin or capex outlook.
Key facts
- Eli Lilly's full-year revenue guidance stands at $91 billion$92 billion. source
- Eli Lilly raised its 2026 sales forecast, with the increase driven by strong performance from Mounjaro and Zepbound. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | unclear | committed | — | Eli Lilly's full-year revenue guidance stands at $91 billion$92 billion. |